Cosmos Health reports stable Q3 revenue and increased equity despite slight revenue drop.

Cosmos Health reported Q3 2024 results with stable revenue and gross profit despite a 3.22% drop to $12.41 million. The company cut expenses by 18.6% and saw stockholders' equity rise 8.8% to $35 million. Key highlights include strong liquidity, over $3.3 million in cash, and record sales at CosmoFarm and Amazon UK. Cosmos Health also entered the development phase for a new gastrointestinal treatment.

November 15, 2024
6 Articles

Further Reading